Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 9/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372787 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372955 | 0.95 | CHRNA7 (0.91) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372956 | 0.95 | CHRNA7 (0.91) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373153 | 0.94 | CHRNA7 (0.89) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372843 | 0.92 | CHRNA7 (0.86) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372844 | 0.92 | CHRNA7 (0.86) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373062 | 0.92 | CHRNB2 (0.84) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL373061 | 0.92 | CHRNB2 (0.84) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL372819 | 0.92 | CHRNA7 (0.84) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL375039 | 0.92 | CHRNA7 (0.84) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2633868-A1 | COMBINATION OF ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | Targacept, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| US-20110059947-A1 | ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | TARGACEPT, INC. (US) | 2011-03-10 | — | — | US | claimed |
| EP-2254598-A2 | ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | Targacept Inc. (US) | 2010-12-01 | — | — | EP | claimed |
| WO-2009102962-A2 | COMBINATION OF ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | TARGACEPT, INC. (US) | 2009-08-20 | — | — | WO | claimed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8541447-B2 | 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2633868-A1 | COMBINATION OF ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | Targacept, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | TARGACEPT, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8158649-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8143272-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8124619-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124620-B2 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | ATTENUA, INC. | 2008-06-12 | — | — | US | disclosed |
| EP-1594869-B1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | ATTENUA, INC. | 2006-11-02 | — | — | US | disclosed |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2005-11-17 | — | — | US | disclosed |
| EP-1594869-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | Targacept, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6953855-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| WO-2004076449-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059947-A1 | ALPHA 7 NICOTINIC AGONISTS AND ANTIPSYCHOTICS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CHRNB2 14/4885CHRNA4 3/4885 |
| US-20080138287-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885CHRNB2 16/4885CHRNA4 8/4885 |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | CHRNA7 1/4885CHRNB2 6/4885CHRNA4 3/4885 |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | CHRM1, CHRNA7, CHRM3 | CHRNA7 2/4885CHRNB2 22/4885CHRNA4 16/4885 |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | CHRNA7, CHRNA1, CHRNA3 | CHRNA7 1/4885CHRNB2 14/4885CHRNA4 11/4885 |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA1 | CHRNA7 1/4885CHRNB2 14/4885CHRNA4 10/4885 |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885CHRNB2 15/4885CHRNA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.